Avaleht › Müeloom › Michigan

Müeloom kliinilised uuringud osariigis Michigan

26 uuringut haiguse Müeloom jaoks otsivad osalejaid osariigis Michigan.

Linnad osariigis Michigan

Ametlik uuringutekst (inglise keeles)

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

START Midwest /ID# 279035, Grand Rapids

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. sept 2026 · NCT07409246

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Karmanos Cancer Institute, Detroit

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07518186

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

University of Michigan Health System, Ann Arbor

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT04634552

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Barbara Ann Karmanos Cancer Institute - Detroit, Detroit

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07393282

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

University of Michigan, Ann Arbor
Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
Cancer And Hematology Centers of Western Michigan PC, Grand Rapids
ja veel 2

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT05552222

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Barbara Ann Karmanos Cancer Institute, Detroit

VärbamineFaas 4

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT05201781

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Trinity Health Ann Arbor Hospital, Ann Arbor
Henry Ford Health Saint John Hospital, Detroit
Genesys Hurley Cancer Institute, Flint
ja veel 7

VärbamineFaas 2

Vanused 12 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT02693535

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT06953960

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Henry Ford Health System, Detroit

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT06980480

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GSK Investigational Site, Grand Rapids

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 19. aug 2026 · NCT05714839

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site, Ann Arbor

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 19. aug 2026 · NCT06106945

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
ja veel 36

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 19. aug 2026 · NCT04566328

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Karmanos Cancer Institute, Detroit

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 18. aug 2026 · NCT06292780

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, Ann Arbor
Research Site, Detroit

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. aug 2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Detroit

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. aug 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

START Midwest, Grand Rapids

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 12. aug 2026 · NCT07280013

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Karmanos Cancer Institute, Detroit
START Midwest, Grand Rapids

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 6. aug 2026 · NCT07284758

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Karmanos Cancer Institute, Detroit

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 8. juuli 2026 · NCT05137054

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

University of Michigan, Ann Arbor
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit

VärbamineFaas 4

Vanused 18 ja vanemad · Kõik sood · Uuendatud 1. juuli 2026 · NCT06057402

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Karmanos Cancer Institute, Detroit
KCI at McLaren Greater Lansing, Lansing

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 26. juuni 2026 · NCT06107738

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Saint Joseph Mercy Hospital, Ann Arbor
Bronson Battle Creek, Battle Creek
Saint Joseph Mercy Brighton, Brighton
ja veel 51

VärbamineFaas 3

Kõik vanused · Kõik sood · Uuendatud 10. juuni 2026 · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Henry Ford St. John Hospital, Grosse Pointe Woods

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 4. juuni 2026 · NCT05243797

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Karmanos Cancer Institute, Detroit
START Midwest, Grand Rapids

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 19. mai 2026 · NCT06433947

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Karmanos Cancer Institute, Detroit

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 13. mai 2026 · NCT05828511

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site, Ann Arbor
GSK Investigational Site, Detroit

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. apr 2026 · NCT06679101

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

Karmanos Cancer Institute, Detroit

Värbamine

Vanused 18 ja vanemad · Kõik sood · Uuendatud 26. aug 2025 · NCT06908629

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.